HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Consumer Results During COVID Show Success From Shifting Entirely To Health Care

Executive Summary

Sales growth for OTC drug brands during latest quarter contribute to Prestige increasing its full-year guidance for FY2022, which ends on 31 March, for revenues growing around 9% to between $1.075bn and $1.08bn.

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Pivoting From Planning Changes To Parsing Results

Inflation's impact on consumer spending will be front and center in sector’s quarterly reports, beginning with J&J on 19 April. Potential impact also from price hikes common from most firms since early 2021 in response to increasing costs. Russia’s invasion of Ukraine also will prompt comment.

With Investor Support Thin On The Ground, Unilever Won't Up Bid For GSK Consumer Healthcare

Unilever's decision not to increase its £50bn bid for GSK Consumer Healthcare has been widely welcomed by analysts. But they warn that the aborted move for GSK has damaged investor confidence in Unilever’s management.

Prestige Consumer Feels ‘5-Ounce Hammer' From Pandemic Headwinds

Prestige hasn’t totally escaped supply chain disruptions caused by shutdowns during the pandemic but it’s relieved to report a smaller impact than most consumer-packaged goods marketers. Slower cough/cold OTC sales also don’t slow its results.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS152175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel